High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma in HIV-Positive Patients in the Highly Active Antiretroviral Therapy Era: The Myeloma Institute of Research and Therapy Experience

2013 ◽  
Vol 13 (2) ◽  
pp. 171-174 ◽  
Author(s):  
Jameel Muzaffar ◽  
Saad Usmani ◽  
Al-Ola Abdallah ◽  
Elias Anaissie ◽  
Michele Cottler-Fox ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Antiretroviral Therapy ◽  
Stem Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Highly Active Antiretroviral Therapy ◽  
High Dose Chemotherapy ◽  
Hiv Positive ◽  
High Dose ◽  
Highly Active

P53 Gene Deletion Detected by Fluorescence In Situ Hybridization Is an Adverse Prognostic Factor for Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4884-4884
Author(s):  
Xiao Ying Qi ◽  
Qi Long Yi ◽  
Donna Reece ◽  
A. Keith Stewart ◽  
Hong Chang
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
P53 Gene ◽  
High Dose Chemotherapy ◽  
High Dose

Abstract We investigated the relevance of p53 deletions to the clinical outcome of multiple myeloma (MM) patients treated with high-dose chemotherapy and autologous stem cell transplantation. Hemizygous p53 gene deletions were detected by cytoplasmic Ig-enhanced interphase fluorescence in situ hybridization (cIg-FISH) in 10 of 105 (9.5%) patients studied. p53 deletions were associated with higher serum calcium (p=0.0062) and creatinine (p=0.013) levels but there were no association with patient age, gender, β-2 microglobulin, C-reactive protein, hemoglobin, albumin, bone lytic lesions, or immunoglobulin isotype. There were no association of p53 deletions with chromosome 13q deletions, translocation t(11;14) or t(4;14). The overall response rates were similar in patients with and without p53 deletions (67% vs 71%). However, patients with p53 deletions had significantly shorter progression free (median 7.9 vs. 25.7 months, p=0.0324) and overall survival (median 14.7 vs. 48.1 months, p=0.0008) than patients without a p53 deletion. A multivariate analysis confirmed p53 deletion was an independent prognostic factor predicting shortened progression free (p=0.0009) or overall survival (p=0.0002) in myeloma patients after high-dose chemotherapy and autologous stem cell transplantation.

Sign in / Sign up

Export Citation Format

Share Document